KIF20A and ovarian carcinoma: Importantly, the systematic analysis by Paul Schossig et al. has positioned KIF20A alongside other TAAs like CT45 and LY6K as promising candidates for immunotherapy in epithelial ovarian cancer, based on high expression levels and prognostic relevance, emphasizing the antigen’s broad therapeutic implications [102].